Structural modification effects on bioactivities of the novel 15-mer peptide adjuvant

Vaccine

Volumn 29, Issue 44, 2011, Pages 7779-7784

  Laman, A G ^a   Shepelyakovskaya, A O ^a   Boziev, Kh M ^a   Savinov, G V ^a,b   Baidakova, L K ^a   Chulin, A N ^a   Chulina, I A ^a   Korpela, T ^c   Nesmeyanov, V A ^a   Brovko, F A ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Adjuvant; Muramyl dipeptide GMDP; Peptide mimetic

Indexed keywords

ALANINE; ARGININE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE DERIVATIVE; OVALBUMIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPEPTIDES; MICE; MICE, INBRED BALB C; OVALBUMIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80053597279     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.113     Document Type: Article

References (23)

1. Ulmer J.B., Valley U., Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol 2006, 24:1377-1383.
2. Sesardic D., Rijpkema S., Patel B.P. New adjuvants: EU regulatory developments. Expert Rev Vaccine 2007, 6:849-861.
3. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5:505-517.
4. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 1974, 59:1317-1325.
5. Windheim M., Lang C., Peggie M., Plater L.A., Cohen P. Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem J 2007, 404:179-190. [Erratum in: Biochem J 2008;409:789].
6. Pabst M.J., Beranova-Giorgianni S., Krueger J.M. Effects of muramyl peptides on macrophages, monokines, and sleep. Neuroimmunomodulation 1999, 6:261-283.
7. Andronova T., Ivanov V. The structure and immunomodulating function of glucosaminylmuramyl peptides. Sov Med Rev D Immunol 1991, 4:1-63.
8. Rostovtseva L.I., Andronova T.M., Malkova V.P., Sorokina I.B., Ivanov V.T. Synthesis and antitumor activity of glycopeptide containing N-acetylglucosaminyl disaccharide unit. Bioorg Khim 1981, 7:1843-1858. (Rus).
9. Nesmeyanov V.A., Khaidukov S.V., Komaleva R.L., Andronova T.M., Ivanov V.T. Muramylpeptides augment expression of Ia-antigens on mouse macrophages. Biomed Sci 1990, 1:151-154.
10. Khaidukov S.V., Komaleva R.L., Nesmeyanov V.A. N-acetylglucosamine-containing muramyl peptides directly affect macrophages. Int J Immunopharmacol 1995, 17:903-911.
11. Tsujimoto M., Kinoshita F., Okunaga T., Kotani S., Kusumoto S., Yamamoto K., et al. Higher immunoadjuvant activities of N-acetyl-beta-d-glucosaminyl-(1-4)-N-acetylmuramyl-l-alanyl-d-isoglutamine in comparison with N-acetylmuramyl-l-alanyl-d-isoglutamine. Microbiol Immunol 1979, 23:933-936.
12. Meshcheryakova E.A., Andronova T.M., Ivanov V.T. A protein interaction network accompanied the signaling pathways activated by muramyl peptides. Bioorg Khim 2010, 36:581-595. (Rus).
13. Sabbah A., Chang T.H., Harnack R., Frohlich V., Tominaga K., Dube P.H., et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009, 10:1073-1080.
14. Laman A.G., Shepelyakovskaya A.O., Berezin I.A., Boziev K.M., Rodionov I.L., Brovko F.A., et al. Identification of pentadecapeptide mimicking muramyl peptide. Vaccine 2007, 25:2900-2906.
15. Rodionov I.L., Baru M.B., Ivanov V.T. A swellographic approach to monitoring continuous-flow solid-phase peptide synthesis. Peptide Res 1992, 5:119-125.
16. Mareeva T.Yu, Kotova O.V., Makarov E.A., Andronova T.M., Nesmeyanov V.A. Monoclonal antibody to N-acetylglucosaminyl-(β1-4)-N-acetylmuramyl-alanyl-d-isoglutamine: preparation and characterization. Bioorg Khim 1993, 19:555-561. (Rus).
17. Law B., Malone M.D., Biddlecombe R.A. Enzyme-linked immunosorbent assay (ELISA) development and optimization. Immunoassay. A practical guide 2005, 133-156. Taylor & Francis e-Library, London. B. Law (Ed.).
18. Meshcheriakova E.A., Gur'ianova S.V., Makarov E.A., Andronova T.M., Ivanov V.T. Bioorg Khim 1991, 17:1157-1165. (Rus).
19. Taki T., Ishikava D., Hamasaki H., Handa S. Preparation of peptides which mimic glycosphingolipids by using phage peptide library and their modulation on beta-galactosidase activity. FEBS Lett 1997, 418:219-223.
20. Harris S.L., Craig L., Mehroke J.S., Rashed M., Zwick M.B., Kenar K., et al. Exploring the basis of peptide-carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies. Proc Natl Acad Sci USA 1997, 94:2454-2459.
21. Johnson M.A., Rotondo A., Pinto B.M. NMR studies of the antibody-bound conformation of a carbohydrate-mimetic peptide. Biochemistry 2002, 41:2149-2157.
22. Johnson M.A., Pinto B.M. Molecular mimicry of carbohydrates by peptides. Aust J Chem 2002, 55:13-25.
23. Johnson M.A., Pinto B.M. Structural and functional studies of peptide-carbohydrate mimicry. Bioactive conformations II. Topics in current chemistry 2008, vol. 273:55-116. Springer-Verlag, Berlin, Heidelberg.